Ian Reid: I think it is appropriate to move back to defining the reference interval for 25(OH)D in the same way that we define other reference intervals, i.e., as the central 95% of the values found in a healthy normal population. Such a range would vary by race and season. If it is possible to reach consensus that adverse health outcomes are causally related to low concentrations of 25(OH)D, then these could be substituted for a conventionally derived interval. However, that consensus does not exist at present, other than for the outcome of osteomalacia, which occurs only in individuals whose 25(OH)D is Ͻ10 ng/mL (25 nmol/L). The progressive increases of the reference interval based on associations of 25(OH)D with health outcomes has
Over the last 20 years there have been numerous studies, including NHANES III (the National Health and Nutrition Examination Survey III), the Women's Health Study, and the Nurses' Health Study, showing an association between decreased 25-hydroxyvitamin D [25(OH)D] 6 concentrations in blood and the risks of cardiovascular disease, stroke, cancer, fractures, and mortality (see the Supplemental Reading List that accompanies the online version of this Q&A at http://www. clinchem.org/content/vol61/issue3). Approximately 10 years ago, these studies led to recommendations from multiple professional societies that the definition of 25(OH)D deficiency be changed from Ͻ20 ng/mL (50 nmol/L) to Ͻ30 ng/mL (75 nmol/L). In the US, we and other institutions saw the volume of 25(OH)D testing increase 5-6-fold between 2004 and 2007 . Furthermore, the use of Ͻ30 ng/mL (75 nmol/L) to define 25(OH)D deficiency results in almost half of the tested population in a large Midwestern US hospital, such as ours, as being vitamin D deficient.
In late 2010, the Institute of Medicine (IOM) issued a report that vitamin D supplementation was unlikely to be beneficial for any condition other than bone health and that blood concentrations of 20 ng/mL (50 nmol/L) or greater were sufficient for maintaining bone health. Since then, several metaanalyses have failed to show that low 25(OH)D concentrations are associated with risk for any of the above-mentioned nonskeletal chronic conditions, with the possible exception of fractures. Ravi Thadhani: The definition of 25(OH)D deficiency should be based on risk for developing a given disorder and/or evidence of bone disease, increased PTH, or decreased calcium. Age, race, and season are all critical in determining expected concentrations; however, the presence of the above alterations should take precedence in defining deficiency.
Will differences in VDBP concentration affect the measurement of 25(OH)D by different immunoassays or mass spectrometry methods?
Karen Phinney: In methods with an extraction step, the 25(OH)D is typically isolated through the addition of organic solvents or other reagents that denature proteins in the sample and release protein-bound species. When developed and applied properly, such methods are not likely to be affected by sample-to-sample differences in VDBP concentration. In automated methods, details of the process for dissociation of 25(OH)D from the VDBP are generally proprietary to the assay platform. There has been at least one report of VDBP concentration affecting the results of automated assays. Heijboer et al. (N Engl J Med 2013; 369:1991 -2000 reported an inverse relationship between VDBP concentration and deviations from the LC-MS/MS comparison method for 4 of the 5 automated assays investigated. One factor limiting the interpretation of these results, however, is the absence of well-established methods for measurement of VDBP concentrations. In addition, genetic variants of the VDBP are believed to have different binding affinities for 25(OH)D. Further study is needed before additional conclusions can be drawn about the impact, if any, of VDBP concentrations on the performance of the many different methods used in clinical laboratories.
Michael F. Holick: Differences in the VDBP concentrations theoretically should not affect the ability of immunoassays to detect total 25(OH)D. However, it is well documented that these assays are often unable to quantitatively detect 25(OH)D 2 . This may be due to either the concentration or binding capacity of the VDBP. This is not observed with LC-MS/MS.
Ravi Thadhani: Approximately 80% of total 25(OH)D is carried by VDBP. VDBP is a negative acute-phase reactant, with a short half-life (1-2 days). In acute conditions such as sepsis, liver production of VDBP goes down, and one should expect concentrations of total 25(OH)D to follow suit. Although most current assays will correctly measure 25(OH)D concentrations, one will more than likely find that patients with acute sepsis are 25(OH)D deficient. The question is whether these patients are truly 25(OH)D deficient, or only appear to be transiently deficient until liver production returns to normal. In my experience, total concentrations of 25(OH)D return to baseline within 1-3 weeks of leaving the intensive care unit (ICU). This is not unlike defining hypothyroidism in patients in the ICU, from where the term "sick euthyroid" emanated.
Aside from acute changes in VDBP, there is some controversy as to the appropriate assay for VDBP. I suggest developing an assay that directly measures bioavailable 25(OH)D (albumin-bound and free 25(OH)D), which will bypass the need to measure VDBP, especially until the differences between assays are sorted out. That said, I believe the genetic differences in VDBP are real, and do account for some portion of the differences in 25(OH)D between blacks and whites. In other words, it is difficult to label all black patients as deficient, when in general their bone health on all fronts is better than that of whites. Therefore, how deficiency is defined should be reexamined, as well as which component of 25(OH)D is the appropriate measure to define 25(OH)D status.
Ian Reid: Yes. Current assays measure total 25(OH)D, which is made up of the free component and that bound to VDBP.
Should we be measuring bioavailable 25(OH)D as opposed to total?
Michael F. Holick: There is not enough information at this time to suggest that the bioavailable 25(OH)D is a better marker for 25(OH)D status as it relates to either bone health or other associated nonskeletal benefits.
Ian Reid: In theory, this would be preferable. However, there are very few VDBP assays available at present, and even fewer direct measurements of free 25(OH)D. There appear to be major technical hurdles to be overcome before such assays are freely available and affordable.
Ravi Thadhani: The concept put forward that bioavailable 25(OH)D is more physiologically important than total concentrations of 25(OH)D is one "borrowed" from the metabolism of other hormones with carrier proteins, such as testosterone and thyroid hormone. While I believe it is the component of 25(OH)D that should be measured, further studies using validated assays (not yet available) are needed before routine use of bioavailable 25(OH)D measurements can be advocated.
Karen Phinney: At the present time, few techniques are available for the direct measurement of either free or bioavailable 25(OH)D, and such techniques are not suited for routine use, nor has their accuracy been assessed.
Mathematical approaches to estimation of bioavailable 25(OH)D have also been reported. These approaches use measured concentrations of VDBP and albumin along with published values for affinity constants for the 3 primary genetic variants of VDBP. The accuracy of methods for the measurement of VDBP has not yet been established, and indeed, the work of Powe et al. showed that there was no significant correlation between two different commercial assays for VDBP. In addition, these computational methods rely upon the availability of genotyping information that is not routinely available. Additional research is needed to demonstrate that measured or estimated bioavailable 25(OH)D is actually linked to particular health outcomes. Finally, given that 25(OH)D is also believed to enter cells through megalin-mediated endocytosis, consideration of only "free" 25(OH)D may overlook other mechanisms of action of 25(OH)D.
Should the recent findings about VDBP polymorphisms affect interpretations about the association of 25(OH)D concentrations with cancer, diabetes, and cardiovascular disease mortality? Should such studies be repeated?
Karen Phinney: The body of evidence supporting an association between VDBP polymorphisms and concentrations of circulating 25(OH)D is growing. There are 3 major variants of the VDBP (GC-1f, GC-1s, GC-2), which can be combined to form 6 diplotypes. Although genetic factors do appear to play a role in observed 25(OH)D concentrations, other factors such as vitamin D intake, season, and ancestry are probably equally important. For example, Gozdzik et al. (J Steriod Biochem Mol Biol 2011; 127:405-12 ) examined young Canadian adults of various ancestries and found that GC-2 alleles were associated with lower 25(OH)D concentrations in East Asians in fall and winter, but no association was observed for South Asians. Malik et al. (Crit Rev Clin Lab Sci 2013; 50:1-22) recently reviewed the available evidence linking variants of the VDBP gene with adverse health outcomes including diabetes, cancer, and infectious diseases. Perhaps not surprisingly, as described in Malik's review, conflicting results have been obtained in some cases, suggesting that other factors such as environment, ethnicity, and lifestyle must be considered. In addition, many of the studies have lacked sufficient statistical power to draw meaningful conclusions. Nevertheless, VDBP polymorphisms clearly add additional complexity to the interpretation of 25(OH)D concentrations and their relationship to health and disease.
Michael F. Holick: There have been several studies suggesting that the polymorphisms for the VDBP as well as the vitamin D receptor may be related to bone health as well as nonskeletal chronic illnesses, including some can-cers. We need larger and better-designed studies to determine the importance of these preliminary observations. Furthermore, studies should be conducted to see whether increasing concentrations of 25(OH)D to Ͼ30 ng/mL (75 nmol/L) can overcome these polymorphic influences.
Ian Reid: It is highly likely that most of these associations between 25(OH)D concentrations and disease simply reflect the fact that people who are unwell, from whatever cause, spend less time exercising outdoors. There is also some evidence that inflammatory conditions reduce concentrations of VDBP, and this may also contribute to some disease associations. The reduced concentration of 25(OH)D in obesity is a further possible contributor. These factors are probably much more important than interracial differences in VDBP polymorphisms.
Ravi Thadhani: The studies should indeed be repeated. The data on genetic polymorphisms, differentiating blacks from whites, are important, and other studies have suggested that polymorphisms in the VDBP gene account for Ͼ10% of the variation of 25(OH)D concentrations in population studies. Genetic differences, in conjunction with accounting for acute changes in VDBP (a negative acute-phase reactant), must also be accounted for in studies of cancer, diabetes, and cardiovascular disease mortality. 
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